| 1.98 0.06 (3.13%) | 04-26 15:49 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.8 | 1-year : | 3.16 |
| Resists | First : | 2.4 | Second : | 2.71 |
| Pivot price | 2.08  |
|||
| Supports | First : | 1.9 | Second : | 1.58 |
| MAs | MA(5) : | 1.95 | MA(20) : | 2.13 |
| MA(100) : | 2.1 |
MA(250) : | 2.37 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 5.9 |
D(3) : | 6.3 |
| RSI | RSI(14): 40.3 |
|||
| 52-week | High : | 3.32 | Low : | 1.71 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CANF ] has closed above bottom band by 33.5%. Bollinger Bands are 109.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.01 - 2.03 | 2.03 - 2.04 |
| Low: | 1.88 - 1.89 | 1.89 - 1.91 |
| Close: | 1.95 - 1.98 | 1.98 - 2 |
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.
Thu, 25 Apr 2024
Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published ... - Business Wire
Mon, 15 Apr 2024
Can-Fite's Namodenoson Shows Promise for Liver Cancer - TipRanks.com - TipRanks
Mon, 15 Apr 2024
Can-Fite's Namodenoson advances in Phase III liver cancer trial - Investing.com
Wed, 03 Apr 2024
Can-Fite Advances MASH Treatment into Phase IIb - TipRanks.com - TipRanks
Wed, 03 Apr 2024
Can-Fite BioPharma seeks FDA nod for NASH drug trial - Investing.com
Mon, 01 Apr 2024
Can-Fite BioPharma Full Year 2023 Earnings: Revenues Disappoint - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 1,220 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 1.4 (%) |
| Shares Short | 77 (K) |
| Shares Short P.Month | 18 (K) |
| EPS | -1.49 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -951.6 % |
| Return on Assets (ttm) | -54 % |
| Return on Equity (ttm) | -142.2 % |
| Qtrly Rev. Growth | -4 % |
| Gross Profit (p.s.) | 0.19 |
| Sales Per Share | 0.19 |
| EBITDA (p.s.) | -2.32 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -1.34 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 10.29 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|